Predictive Oncology – Year-end Shareholder Update!

EAGAN, Minnesota, December 21, 2021 (GLOBE NEWSWIRE) – Predictive Oncology, (POAI), a knowledge-driven company focused on the application of artificial intelligence (AI) to develop personalized cancer therapies, is moving in the right direction.

In November 2021, POAI acquired zPREDICTA, a leading cancer company with a proven business and scientific record. Their patented 3D cell culture platform has already proven itself. ZPREDICTA technology has been validated in multiple myeloma and cell growth. We believe this is the only cell culture model derived from human bone marrow capable of maintaining primary multiple myeloma cells. The science is now being adapted to other cultures of cancer cells.

In addition to the synergies already present with our Helomics and TumorGenesis divisions, the acquisition opens the door for POAI to large pharmaceutical clients already doing business with zPREDICTA. We now have a one-two punch for pharma with the established 3D cell culture platform and our CoRE ™ artificial intelligence technology that will reduce the cost and time of drug discovery and drug reorientation. .

zPREDICTA brings historic revenue stream and profitable bottom line to POAI. Coupled with the anticipated commercialization of our Discovery 21 project, POAI is in the process of transitioning from a research and development only company to a revenue-based biopharmaceutical company.

To support our marketing efforts, POAI announced the hiring of Pamela Bush, Ph.D, MBA, on December 7, 2021. Dr. Bush will lead our sales and business development initiatives, while integrating our sales and development efforts. marketing throughout the company.

Predictive Oncology consists of four interwoven divisions: Helomics, TumorGenesis, Soluble Biotech and, now, zPREDICTA. Our former company, Skyline Medical, continues to sell the STREAMWAY System®, generating revenue and covering its own costs, while we consider options to sell the division.

By working together, we strive to eliminate cancer while delivering strong returns to our investors.

Thank you,

J. Melville (“Mel”) Engle

About predictive oncology

Predictive Oncology Inc. (NASDAQ: POAI) is a knowledge-driven company focused on the application of artificial intelligence (AI) to develop personalized cancer therapies, which can lead to more effective treatments and better patient outcomes. Using artificial intelligence, Predictive Oncology uses a database of more than 150,000 cancerous tumors, categorized by patient type, against drug compounds to determine the optimal therapies to use to ultimately eliminate cancer.

As the drug discovery community has now understood, a genomics-based approach to cancer research and drug development is insufficient to realize the promise of personalized therapy. Rather, predictive oncology takes a multiomic approach, which takes into account the vast multitude of factors that make each cancer unique.

Forward-Looking Statements: Certain matters discussed in this press release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections regarding future events and are subject to substantial risks, uncertainties and assumptions regarding our operations and the investments we make. All statements, other than statements of historical fact, included in this press release regarding our strategy, future operations, future financial condition, future revenues and financial performance, projected costs, prospects, plans and Management’s objectives are forward-looking statements. The words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “,, all forward-looking statements do not contain these words. ‘identification. Our actual future performance may differ materially from that contemplated in forward-looking statements due to various factors, including, but not limited to, the risks associated with the acquisition of zPREDICTA, including no assurance of future operating results of zPREDICTA, no assurance that zPREDICTA customers will continue to use zPREDICTA services at historical levels or not at all, the risk of higher than expected expenses, the integration risk, the risk of future goodwill impairment that would impact POAI’s operating results and dependence on management and employees of zPREDICTA, and the factors discussed under “Risk Factors” in our filings with the SEC. Unless expressly required by law, the Company disclaims any intention or obligation to update these forward-looking statements.

Investor Relations Contact:
Landon Capital Keith Pinder (404) 995-6671
[email protected]

Source link

About Margie Peters

Check Also

Rupifi Raises $ 25 Million in Serie A Funding Round

Fintech start-up Rupifi has raised a funding round of $ 25 million from Bessemer Venture …